Remembering Henri Beaufour's Impact at Ipsen
It is with profound sadness that the team at Ipsen reflects on the passing of Henri Beaufour, a cherished Board Member and a representative of the founding family of Ipsen. Henri, who passed away on a recent Friday, embodied the legacy of dedication and passion for the biopharmaceutical industry.
A Pillar of Ipsen’s Development
Throughout his tenure, Henri Beaufour, alongside his sister, played a crucial role in steering Ipsen towards its strategic goals while firmly upholding the values instilled by the Beaufour family. The Board of Directors, along with the Executive Leadership Team, extends their heartfelt condolences to Henri's family, acknowledging the profound impact his life and work had on the Ipsen community.
Leadership Reflections
Henri Beaufour leaves behind a rich legacy of leadership and commitment. He was not only a devoted Director but also a significant shareholder who cared deeply about the company’s growth. His artistic talents and kindness resonated within and beyond the office walls, perpetuating the values of his grandfather, the company’s founder. Marc de Garidel, Chairman of Ipsen, highlighted how the Board remains devoted to pursuing the strategic priorities initiated by Henri’s late father, Albert Beaufour.
Future Directions for Ipsen
As Ipsen moves forward, Beech Tree and Highrock, the controlling shareholders, reaffirm their commitment to act jointly for the best interests of Ipsen. David Loew, Chief Executive Officer, expressed deep sorrow over Henri's passing, emphasizing the leadership team's resolve to continue pushing Ipsen forward in his honor. His memory will serve as a guiding force for all at the company.
About Ipsen: Transforming Biopharmaceuticals
With a global footprint, Ipsen is dedicated to innovating transformative medicines across various therapeutic areas, including Oncology, Rare Disease, and Neuroscience. The company’s rich legacy spans nearly 100 years and involves advancing a robust pipeline fueled by both internal and external innovation. Ipsen's teams operate in over 40 countries, delivering medicines to patients across the globe, with key hubs in the United States, France, and the United Kingdom.
Contacting Ipsen: Staying Connected
For inquiries, interested parties may reach out to the dedicated team at Ipsen:
Investors
Henry Wheeler – henry.wheeler@ipsen.com – +33 764471149
Khalid Deojee – khalid.deojee@ipsen.com – +33 666019526
Media
Sally Bain – sally.bain@ipsen.com – +1 8573200517
Anne Liontas – anne.liontas.ext@ipsen.com – +33 767347296
Frequently Asked Questions
Who was Henri Beaufour?
Henri Beaufour was a longtime Board Member of Ipsen and a vital part of the founding family, playing a crucial role in the company's strategic development.
What contributions did he make to Ipsen?
Henri contributed significantly to steering the company towards its strategic goals while supporting its core values and fostering a culture of kindness and generosity.
Who expressed condolences on his passing?
The Board of Directors and Executive Leadership Team at Ipsen, along with his family and many others touched by his life, expressed their heartfelt condolences.
How will Ipsen honor Henri Beaufour's memory?
The leadership team, under the guidance of Marc de Garidel and David Loew, is committed to advancing the company's mission and values in his honor.
What is Ipsen’s area of focus?
Ipsen is a global biopharmaceutical company focused on developing transformative medicines in Oncology, Rare Disease, and Neuroscience.
